MetaCap

Bruker (BRKR) vs Pacific Biosciences of California (PACB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Bruker (BRKR) has outperformed Pacific Biosciences of California (PACB) over the past year, gaining 19.4% versus a loss of 26.6%. Over five years, BRKR leads with a -32.2% price change compared with -93.0% for PACB. Bruker is the larger company by market cap ($8.62 billion vs $508.9 million), about 16.9 times the size, while Pacific Biosciences of California is growing revenue faster (+3.9% vs +2.1%).

Bruker pays a dividend yielding 0.09%, while Pacific Biosciences of California does not currently pay one. Bruker converts more of its revenue into profit, with a net margin of -0.3% versus -341.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BRKR+19.44%PACB-26.58%
+45%-5%-55%
Nov 21, 20251 yearNov 20, 2026
BRKR-32.64%PACB-93.84%
+18%-42%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BRKR versus PACB key metrics
MetricBRKRPACB
Share price$56.46$1.63
Market cap$8.62B$508.95M
1-day change-9.08%-7.39%
YTD return+19.85%-12.83%
1-year return+19.44%-26.58%
5-year return-32.16%-93.01%
Forward P/E23.25—
EPS (TTM)$-1.10$-0.42
Dividend yield0.09%0.00%
Annual dividend$0.05$0.00
Revenue (latest FY)$3.44B$160.00M
Revenue growth (YoY)+2.08%+3.89%
Net income (latest FY)$-8.60M$-546.38M
Gross margin45.91%28.61%
Operating margin1.98%-346.15%
Net margin-0.25%-341.47%
52-week high$68.98$3.44
52-week low$32.37$1.07
Distance from 52-week high-18.15%-52.62%
Analyst consensusbuybuy
Avg. price target upside+20.44%+68.10%
Average volume2.32M13.23M
Shares outstanding152.72M312.24M
Employees11,085485
SectorIndustrialsIndustrials
IndustryBiotechnology: Laboratory Analytical InstrumentsBiotechnology: Laboratory Analytical Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Bruker is about 16.9 times larger than Pacific Biosciences of California by market value ($8.62B vs $508.95M).
  • BRKR has outperformed PACB by 46.0 percentage points over the past year.
  • Bruker is more profitable, keeping -0.3 cents of every revenue dollar as net income versus -341.5 cents for Pacific Biosciences of California.

About Bruker

BRKR stock →

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

Industrials · Biotechnology: Laboratory Analytical Instruments · 11,085 employees

About Pacific Biosciences of California

PACB stock →

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.

Industrials · Biotechnology: Laboratory Analytical Instruments · 485 employees

BRKR vs PACB FAQ

Which is bigger, Bruker or Pacific Biosciences of California?

Bruker (BRKR) is larger, with a market capitalization of $8.62B compared with $508.95M for Pacific Biosciences of California (PACB).

Which stock has performed better over the past year, BRKR or PACB?

BRKR returned +19.44% over the past 12 months, compared with -26.58% for PACB (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Bruker or Pacific Biosciences of California?

Bruker pays a dividend yielding 0.09%, while Pacific Biosciences of California does not currently pay a regular dividend.

Are Bruker and Pacific Biosciences of California in the same industry?

Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.

More comparisons